Adults with congenital adrenal hyperplasia treated with an oral nonsteroidal drug saw continued disease control with reduced ...

Neurocrine Biosciences has presented new one-year data from its Phase III CAHtalyst Adult study of Crenessity (crinecerfont) ...

Adrenal hormone function was restored in animal studies, potentially paving the way for a functional cure for primary adrenal ...

Crinecerfont is associated with sustained reductions in androstenedione and GC doses at 1 year in congenital adrenal hyperplasia.

INTRODUCTION Congenital adrenal hyperplasia (CAH) comprises a group of autosomal recessive diseases that affect the synthesis of cortisol. Most CAH result from mutations in a single gene, which ...

Boys and young adult male patients with congenital adrenal hyperplasia receiving glucocorticoid treatment have lower bone mineral density than healthy individuals, an Italian study shows.

After seven decades with no advances in the treatment of congenital adrenal hyperplasia, Neurocrine has scored an FDA approval for Crenessity.

Neurocrine Biosciences announced that the FDA has approved crinecerfont as an adjunct to glucocorticoid replacement to control androgens for patients with congenital adrenal hyperplasia ...

The approval was based on phase 3 data from the randomized, double-blind, placebo-controlled CAHtalyst adult study and CAHtalyst pediatric study. The FDA has approved Crenessity (crinecerfont) for ...

References: Neurocrine Biosciences announces FDA approval of Crenessity™ (crinecerfont), a first-in-class treatment for children and adults with classic congenital adrenal hyperplasia. News release.

Classic congenital adrenal hyperplasia is a rare genetic condition affecting the adrenal glands, which produce hormones such as cortisol and androgens. Patients with classic CAH do not produce enough ...

Neurocrine's CRENESSITY Gains FDA Approval For Treating Congenital Adrenal Hyperplasia December 13, 2024 — 07:52 pm EST Written by RTTNews.com for RTTNews -> ...